By Jordan M. Johnson, MSHA, MLS | Founder and CEO, Bridge Oncology
For years, oncology leaders have negotiated inside a fog. Programs knew their own reimbursement, suspected what competitors received, and relied on fragmented information to make decisions about contracts, growth, and sustainability.
That fog is beginning to lift.
On October 5, 2026, federal agencies finalized updates to the Transparency in Coverage rules. The changes include network-level payer rate files, specialty-based filtering, new taxonomy and utilization files, quarterly updates, and attestations accompanied by a named senior official. Reporting will also better align with hospital price-transparency disclosures. The core rate-file amendments apply five months after Federal Register publication; the new contextual files follow at 11 months.[1]
For oncology, the strategic question is straightforward: when prices become easier to compare, can your program explain the value behind them?
A clearer price creates a harder conversation
Consider two oncology programs treating clinically comparable patients. One operates in a hospital outpatient department. The other operates in a physician office or freestanding center. Their negotiated prices may differ substantially.
Better data could make those differences easier for employers and payers to examine. Our expectation is that this will strengthen site-of-care negotiations and sharpen questions about what a higher price actually purchases.
Hospitals may have legitimate reasons for higher costs: complex patients, emergency support, infrastructure, and services that smaller settings cannot sustain. But those responsibilities must be measured and explained. A hospital affiliation alone is a weak negotiating argument.
The same discipline applies to independent practices. A lower price does not establish better care. Programs must demonstrate clinical appropriateness, reliable delivery, patient experience, and access.
Every organization should be prepared to connect its price to its performance.
Radiation oncology needs a fuller economic picture
This is particularly relevant to radiation oncology, where debates about payment reform can consume attention while the underlying operation remains poorly understood.
A Medicare case-rate proposal such as ROCR addresses a particular payment framework. It does not, by itself, establish what a complete cancer episode costs across local payer contracts and sites of care.
A stronger model asks broader questions.
What does an appropriate course cost under each commercial contract? How does evidence-based hypofractionation affect reimbursement, treatment capacity, and patient travel? What happens when systemic therapy, imaging, supportive care, and acute-care use are included?
Public prices can help inform those calculations. They cannot complete them.
Programs still need their own claims, clinical information, contract terms, utilization patterns, and operating costs. Comparisons must account for patient complexity and treatment intent. A published rate is neither a guaranteed payment nor an explanation of why a service was needed.
This is where the accountable oncology enterprise becomes practical: clinical decisions, operational performance, and financial consequences must be understood together.
Revenue integrity belongs in the conversation
The new taxonomy disclosures also deserve attention. They expose specialty-to-service mappings or related rules used to filter payer rate files.[1]
For oncology teams, that creates another reference point when investigating provider classification, credentialing, or specialty-related payment problems.
It does not replace coverage policies, authorization requirements, or claim-level review. It can, however, help teams ask more precise questions when a payer’s published information does not match the services a program actually provides.
Transparency becomes useful when someone owns the reconciliation.
Patients need an answer they can use
The rule also adds telephone access to payer cost-sharing information for plan or policy years beginning on or after January 1, 2027.[1]
That matters because cancer patients need more than a spreadsheet. They need someone who can explain likely financial responsibility, benefit timing, and available assistance before treatment creates another crisis.
Financial navigation should connect the estimate to the actual treatment plan and follow discrepancies through resolution.
Begin before the next contract negotiation
Oncology leaders should start with their largest payer relationships, highest-spend services, and most consequential operational decisions. Establish a defensible rate baseline. Validate comparable billing components and sites. Pair price analysis with clinical outcomes, capacity, and patient burden.
At Bridge Oncology, we believe sustainable access depends on organizations understanding how their care is delivered, what it costs, and why it creates value.
Price transparency gives leaders another tool to do that work.
The organizations that can explain their economics will be better positioned to negotiate their future. Those that cannot risk having someone else explain it for them.
[1] CMS, “Transparency in Coverage Final Rules (CMS 9882-F),” October 5, 2026. https://www.cms.gov/newsroom/fact-sheets/transparency-coverage-final-rules-cms-9882-f
Based on Bridge Oncology’s Transparency in Coverage Final Rule Brief. Strategic implications represent Bridge Oncology analysis.